On July 17, the Food and Drug Administration (TFDA) of the Ministry of Health and Welfare, Republic of China, announced that Dong Sheng Hwa Pharmaceutical Co., Ltd. initiated a voluntary recall of “Linicor F.C.T. 500/20mg” after the manufacturer reported that long-term stability testing revealed the active ingredient content did not conform to the original approved specifications.

Basic Information of Recalled Medication:

  • Product Name: Linicor F.C.T. 500/20mg (理脂膜衣錠 500/20 毫克)
  • Indications: Hyperlipidemia in patients suitable for combined treatment with Niacin and lovastatin. Patients should initiate a standard cholesterol-lowering diet prior to receiving Linicor and continue this diet throughout Linicor therapy.
  • Active Ingredients: LOVASTATIN, NIACIN
  • License Number: DOH-MD-No. 057216
  • Batch Number: AFC431
  • License Holder: Dong Sheng Hwa Pharmaceutical Co., Ltd.

Recall Details

  • Recall Classification: Class II[i]
  • Official Dispatch No.: FDA-Yao-Zi No. 1066037938 (TFDA Medicinal Products Division)
  • Dispatch Date: July 17, 2017
  • Announcement Date: July 27, 2017
  • Reason for Recall: Voluntary notification by the manufacturer stating that long-term stability testing showed the active ingredient content of the specified batch did not meet approved specifications.
Further Reading
  1. Introduction to the TFDA Drug Recall Classification System and Disposal Measures
✦ Independent Journalism · Reader Support ✦

Support Independent Perspectives & In-Depth Insights

Every thoughtful analysis and candid critique comes from our dedication to truth and quality. We choose not to follow sensational algorithms or clickbait headlines.

Sustaining independent research requires reader support. Make a one-time or monthly contribution, securely processed by Google.

Payments secured by Google · Manage or cancel anytime in your Google Account